Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

Genmab chief executive Jan van de Winkel said that the company was "disappointed" by J&J's exit from the alliance. Still, he stressed that the strength of other programmes – including AbbVie ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Genmab and partner AbbVie (ABBV) are seeing continued good traction of Epkinly, and Genmab says that physicians are providing good feedback since last summer’s approval for relapsed/refractory ...

We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...

and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. Market Capitalization Analysis: The company's ...

and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. Breaking Down Genmab's Financial Performance ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Highlights from Woyach, professor in the division of hematology at The Ohio State University, include a study that evaluated epcoritamab (Epkinly; Genmab, AbbVie) monotherapy, and another that ...